Quest Magazine

MMD Research: 'Bright' Prospect

Researchers at the University of Rochester (N.Y.) Wellstone Muscular Dystrophy Cooperative Research Center have identified a compound that has the potential to be developed into a treatment for type 1 myotonic dystrophy (MMD1, or DM1).

The compound, dubbed CAG25, is an "antisense oligonucleotide," a type of construct that's been used to block disease-causing genetic instructions in laboratory experiments and human trials in other diseases.

Conference Focuses on Becker MD

An MDA-supported conference for families and professionals interested in scientific, medical and social issues related to Becker muscular dystrophy (BMD) will take place Aug. 1, 2009, at Massachusetts General Hospital in Boston.

The one-day conference is free, but seating is limited and attendees must register by July 24.

The program features:

ALS Research: No Smoking Gun

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

ALS Research: No Smoking Gun

 

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

“Show me the money!” MDA greenlights grants

At a time when federal and private funds for biomedical research have become scarce, the Muscular Dystrophy Association reasserts its leadership in the fight against muscle diseases by announcing grants to innovative research projects throughout America and in Canada.

“Federal support for the type of work we do has just about dried up, especially in the current economic climate.  Simply put, without the support of MDA, this line of investigation could not be pursued by our lab,” said Eric Schon, researcher at Columbia University Medical Center in New York.

No Smoking Gun

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

MMD1 Research: Iplex Shows Limited Benefit

The drug Iplex, developed by the Richmond, Va., biopharmaceutical company Insmed, did not improve muscle function, strength or endurance in a phase 2 trial in type 1 myotonic dystrophy (MMD1, or DM1), the company announced June 25, 2009. (See Insmed Announces Results.)

Iplex Shows Limited Benefit in MMD1

The drug Iplex, developed by the Richmond, Va., biopharmaceutical company Insmed, did not improve muscle function, strength or endurance in a phase 2 trial in type 1 myotonic dystrophy (MMD1, or DM1), the company announced June 25, 2009. (See Insmed Announces Results.)

MMD: Insmed Announces Results

RICHMOND, VA., June 25, 2009 - Insmed Inc. (NASDAQ CM: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX™ (mecasermin rinfabate) in patients with myotonic muscular dystrophy (“MMD”).  The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S.

MD Research: 3-Protein Repair Cluster

Scientists in the United States and Japan have identified a three-protein cluster that reseals damaged muscle-fiber membranes. The findings, published June 5, 2009, in the Journal of Biological Chemistry, could have implications for development of treatments for muscular dystrophies.

Pages